In the United States, glaucoma represents about 9% to 12% of blindness, affecting over 100,000 people. It's also the leading cause of blindness for African Americans and Hispanics in the US. Over 4 million people in the US are diagnosed with it.
The use of cannabis (marijuana) as a treatment for glaucoma has received much press over the years, usually as a point of contention in the larger debate over the legalization of the drug. While the American Academy of Ophthalmology (AAP) has acknowledged that ingestion of cannabis derivatives does reduce intraocular pressure, their official position is that there is no scientific evidence that cannabis is better for glaucoma treatment than the current FDA approved pharmaceuticals.